Ernexa presents preclinical data on ERNA-101 at MD Anderson

Erxnea Therapeutics, a company specializing in cell therapies for advanced cancer treatment, revealed preclinical data for its lead drug, ERNA-101, on October 6, 2026. The data was to be presented at the Next-Generation Cancer Therapeutics meeting hosted by MD Anderson Cancer Center in Houston. ERNA-101, an allogeneic, off-the-shelf, induced pluripotent stem cell-derived mesenchymal stromal cells, was engineered to express IL-7 and IL-15.

The therapy is designed to deliver an immune-activating cytokine payload to the tumor microenvironment. Preclinical models of high-grade serous ovarian cancer showed that ERNA-101 promoted immune cell recruitment, induced tumor regression, and enhanced survival. When combined with PD-1 checkpoint blockade, the drug achieved complete tumor control and durable responses in the majority of treated animals.

Biodistribution studies confirmed localized tumor microenvironment targeting, with no detectable presence in other organs. The selection of ERNA-101 for presentation at this prestigious meeting underscores the strength of its preclinical findings. Ernexa Therapeutics is currently progressing ERNA-101 toward clinical development for ovarian cancer.